August 05, 2015 – Aquinox Pharmaceuticals Inc.
VANCOUVER, British Columbia, Aug. 5, 2015 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox’s President & CEO, will present a corporate overview at the upcoming Canaccord Genuity 35th Annual Growth Conference on Thursday, August 13th at 3:00 PM Eastern Time.
A live audio and visual webcast and archive of the event will be available at: www.com/webcast/canaccord18/aqxp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast, as well as the corporate overview being presented, will be available on the Investor Relations page of Aquinox’s website at: www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox’s lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit: www.aqxpharma.com.
Investor Contact Info:
Brendan Payne, Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
Communications Contact Info:
Heather Savelle , Vice President
MacDougall Biomedical Communications